M
Mickael Aoun
Researcher at Institut Jules Bordet
Publications - 22
Citations - 1657
Mickael Aoun is an academic researcher from Institut Jules Bordet. The author has contributed to research in topics: Population & Febrile neutropenia. The author has an hindex of 11, co-authored 21 publications receiving 1371 citations. Previous affiliations of Mickael Aoun include Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan Maertens,Issam I Raad,Kieren A. Marr,Thomas F. Patterson,Dimitrios P. Kontoyiannis,Oliver A. Cornely,Eric J. Bow,Galia Rahav,Dionysios Neofytos,Mickael Aoun,John W. Baddley,Michael Giladi,Werner J. Heinz,Raoul Herbrecht,William W. Hope,Meinolf Karthaus,Dong-Gun Lee,Olivier Lortholary,Vicki A. Morrison,Ilana Oren,Dominik Selleslag,Shmuel Shoham,George Richard Thompson,Misun Lee,Rochelle Maher,Anne Schmitt-Hoffmann,Bernhardt Zeiher,Andrew J. Ullmann +27 more
TL;DR: The results support the use of isavuconazole for the primary treatment of patients with invasive mould disease and non-inferiority was shown.
Journal ArticleDOI
Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High–Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)
Oliver A. Cornely,Johan Maertens,Mark Bresnik,Ramin Ebrahimi,Andrew J. Ullmann,Emilio Bouza,Claus Peter Heussel,Olivier Lortholary,Christina Rieger,Angelika Boehme,Mickael Aoun,Heinz-August Horst,Anne Thiebaut,Markus Ruhnke,Dietmar Reichert,Nicola Vianelli,Stefan W. Krause,Eduardo Olavarria,Raoul Herbrecht +18 more
TL;DR: In highly immunocompromised patients, the effectiveness of 3 mg/kg of liposomal amphotericin B per day as first-line therapy for invasive aspergillosis is demonstrated, with a response rate of 50% and a 12-week survival rate of 72%.
Journal ArticleDOI
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
Alemnew F Dagnew,Osman Ilhan,Won Sik Lee,Dariusz Woszczyk,Jae Yong Kwak,Stella Bowcock,Sang Kyun Sohn,Gabriela Rodriguez Macías,Tzeon Jye Chiou,Dimas Quiel,Mickael Aoun,Maria Belen Navarro Matilla,Javier de la Serna,Sam Milliken,John Murphy,Shelly A. McNeil,Bruno Salaun,Emmanuel Di Paolo,Laura Campora,Marta López-Fauqued,Mohamed El Idrissi,Anne Schuind,Thomas C. Heineman,Peter Van den Steen,Lidia Oostvogels,Kadir Acar,Boris Afanasyev,Aránzazu Alonso Alonso,Veli-Jukka Anttila,Pere Barba Suñol,Norbert Blesing,Terrance Comeau,Teresa del Campo,Patricia Disperati,Richard Eek,Hyeon Seok Eom,Gianluca Gaidano,Sebastian Grosicki,Thierry Guillaume,Wojciech Homenda,William Hwang,Nikolay Ilyin,Anna Johnston,Seok Jin Kim,Ching Yuan Kuo,Aleksey Kuvshinov,Dong-Gun Lee,Jae Hoon Lee,Je Jung Lee,Stephane Lepretre,Albert Kwok Wai Lie,Alessandro Lucchesi,Ahmed Masood,Naheed Mir,Anna Carolina Miranda Castillo,Kathleen M. Mullane,Alexandr Myasnikov,Raquel Oña Navarrete,Karlis Pauksens,Andrew Peniket,Jaime Pérez de Oteyza,David Pohlreich,Humphrey Pullon,Philippe Quittet,Philippe Rodon,Lars Rombo,Olga Samoylova,Johan Sanmartin Berglund,Ariah Schattner,Dominik Selleslag,Marjatta Sinisalo,Faisal Sultan,Koen Theunissen,Paul Turner,Po Nan Wang,Lucrecia Yáñez San Segundo,Jo Anne H. Young,Pierre Zachee,Francesco Zaja +78 more
TL;DR: The immunocompromised adult population with haematological malignancies is at high risk for herpes zoster and the adjuvanted recombinant zoster vaccine, which is currently licensed in certain countries for adults aged 50 years and older, is likely to benefit this population.
Journal ArticleDOI
Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
Imran Ahmad,Nguyen V. Cau,John Kwan,Younes Maaroufi,Nathalie Meuleman,Mickael Aoun,Philippe Lewalle,Philippe Martiat,Françoise Crokaert,Dominique Bron +9 more
TL;DR: A PCR-guided and rituximab-based preemptive approach to avoid PTLD after allogeneic hematopoietic stem-cell transplantation is feasible but probably overtreated patients.
Journal ArticleDOI
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease
Oliver A. Cornely,Michael N. Robertson,Shariq Haider,Andrew Grigg,Michelle Geddes,Mickael Aoun,Werner J. Heinz,Issam I Raad,Urs Schanz,Ralf G. Meyer,Sarah P. Hammond,Kathleen M. Mullane,Helmut Ostermann,Andrew J. Ullmann,Stefan Zimmerli,M. L.P.S. Van Iersel,Deborah A. Hepler,Hetty Waskin,Nicholas A. Kartsonis,Johan Maertens +19 more
TL;DR: Intravenous posaconazole at 300 mg was well tolerated, resulted in adequate steady-state systemic exposure and was associated with a low incidence of IFD in this population at high risk.